Victory Capital Management Inc. Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Victory Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 42,909 shares of the biopharmaceutical company’s stock after purchasing an additional 4,229 shares during the period. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $11,801,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ALNY. Plato Investment Management Ltd lifted its stake in Alnylam Pharmaceuticals by 2,666.3% in the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 4,346 shares in the last quarter. Diversified Trust Co purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $1,210,000. Los Angeles Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares in the last quarter. Breakwater Capital Group purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $249,000. Finally, Sanctuary Advisors LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $578,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 6.2 %

NASDAQ ALNY opened at $248.79 on Thursday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a market cap of $32.09 billion, a PE ratio of -94.96 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm’s fifty day moving average is $273.83 and its two-hundred day moving average is $236.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.15 EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday. Raymond James lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Citigroup lifted their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.